Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness
Julie Leca, … , Sophie Vasseur, Richard Tomasini
Julie Leca, … , Sophie Vasseur, Richard Tomasini
Published October 4, 2016
Citation Information: J Clin Invest. 2016;126(11):4140-4156. https://doi.org/10.1172/JCI87734.
View: Text | PDF
Research Article Cell biology Oncology

Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness

Abstract

The intratumoral microenvironment, or stroma, is of major importance in the pathobiology of pancreatic ductal adenocarcinoma (PDA), and specific conditions in the stroma may promote increased cancer aggressiveness. We hypothesized that this heterogeneous and evolving compartment drastically influences tumor cell abilities, which in turn influences PDA aggressiveness through crosstalk that is mediated by extracellular vesicles (EVs). Here, we have analyzed the PDA proteomic stromal signature and identified a contribution of the annexin A6/LDL receptor-related protein 1/thrombospondin 1 (ANXA6/LRP1/TSP1) complex in tumor cell crosstalk. Formation of the ANXA6/LRP1/TSP1 complex was restricted to cancer-associated fibroblasts (CAFs) and required physiopathologic culture conditions that improved tumor cell survival and migration. Increased PDA aggressiveness was dependent on tumor cell–mediated uptake of CAF-derived ANXA6+ EVs carrying the ANXA6/LRP1/TSP1 complex. Depletion of ANXA6 in CAFs impaired complex formation and subsequently impaired PDA and metastasis occurrence, while injection of CAF-derived ANXA6+ EVs enhanced tumorigenesis. We found that the presence of ANXA6+ EVs in serum was restricted to PDA patients and represents a potential biomarker for PDA grade. These findings suggest that CAF–tumor cell crosstalk supported by ANXA6+ EVs is predictive of PDA aggressiveness, highlighting a therapeutic target and potential biomarker for PDA.

Authors

Julie Leca, Sébastien Martinez, Sophie Lac, Jérémy Nigri, Véronique Secq, Marion Rubis, Christian Bressy, Arnauld Sergé, Marie-Noelle Lavaut, Nelson Dusetti, Céline Loncle, Julie Roques, Daniel Pietrasz, Corinne Bousquet, Stéphane Garcia, Samuel Granjeaud, Mehdi Ouaissi, Jean Baptiste Bachet, Christine Brun, Juan L. Iovanna, Pascale Zimmermann, Sophie Vasseur, Richard Tomasini

×

Figure 3

CAF-mediated support to cancer cells depends on ANXA6 present within the ternary complex.

Options: View larger image (or click on image) Download as PowerPoint
CAF-mediated support to cancer cells depends on ANXA6 present within the...
(A) Graphical representation of the culture protocol for measuring PANC-1 cell viability (median ± interquartile range, n = 3). ***P < 0.001, Mann-Whitney U test. (B) Graphical representation of the culture protocol for measuring PANC-1 migration ability (median ± interquartile range, n = 3). **P < 0.05, Mann-Whitney U test. (C) Graphical representation of the culture protocol for measuring PANC-1 adhesion ability (median ± interquartile range, n = 3). ***P < 0.001, Mann-Whitney U test. (D) Western blot of the indicated proteins in lysates established from CAFs infected with shRNA control (shCtr, #7 and #3) or shRNAs against ANXA6 (shANXA6-1 and shANXA6-2, #7 and #3). Quantifications are expressed as fold increase compared with CAFs infected with shCtr, n = 3. (E) Western blot of the indicated proteins following endogenous coimmunoprecipitation with nonrelevant antibody (NR) as negative control or anti-LRP1 antibody in protein lysates from CAFs infected with shCtr or shANXA6s under pathophysiologic conditions. TCL, total cell lysates. Quantifications are expressed as fold increase compared with the NR condition; data are representative of 3 independent experiments. (F) PANC-1 viability assay as in A with CAFs infected with shCtr or shANXA6s under pathophysiologic conditions (median ± interquartile range, n = 3). **P < 0.01, Mann-Whitney U test. (G) PANC-1 migration assay as in B with CAFs infected with shCtr or shANXA6s under pathophysiologic conditions (median ± interquartile range, n = 3). ***P < 0.001, Mann-Whitney U test. (H) PANC-1 adhesion assay as in C with CAFs infected with shCtr or shANXA6s under pathophysiologic conditions (median ± interquartile range, n = 3). *P < 0.05, **P < 0.01, Mann-Whitney U test. For A–C and F–H, data are expressed as fold increase compared with PANC-1 alone.